This application claims the priority of Chinese Patent Application No. 201710963119.2, filed on Oct. 17, 2017, and the disclosures of which are hereby incorporated by reference.
The present disclosure relates to the field of microbe technology, specifically to a Lactobacillus reuteri and use thereof, especially to a Lactobacillus reuteri that is capable of modulating intestinal flora, modulating brain-gut axis and significantly alleviating metabolic syndrome, and use thereof.
Recent years, with the developing economy, life-styles of people in many countries have changed obviously. With the amount of physical activity has decreased, obesity rate has increased significantly, and prevalence rates of diabetes and metabolic syndrome have increased by a large margin. An epidemiology survey shows that 20% to 30% of the adults across the globe are suffering from metabolic syndrome. In 2013, a multicenter, multistage stratified, large-scale sampling survey carried out by Chinese Diabetes Society of Chinese Medical Association showed that among people over 20 years old in large and medium-sized cities, towns and countryside of China, prevalence rates of metabolic syndrome in men and women were 16.7% and 11.7%, respectively, and the total prevalence rate was 13.7%. Furthermore, the rate was continuously increasing. Analyses show that age, blood pressure, diabetes family history, obesity, hyperlipidemia, male, low income and little exercise are main related risk factors for metabolic syndrome. The survey also found that the rates of the overweight and the obesity among people have increased by a large margin, and prevalence rate of metabolic syndrome of male is significant higher than that of female at the same age among middle-aged crowd.
Metabolic syndrome is a clinical syndrome, which has simultaneous symptoms of central obesity, fasting blood glucose rising, high blood pressure, decrease of high-density lipoprotein cholesterol and increase of triacylglycerol, in which numerous hazardous factors basing on the abnormal pathological changes of carbohydrate metabolism, lipid metabolism and protein metabolism aggregates, and which promotes development of diabetes (type II) and cardiovascular diseases such as atherosclerosis and so on. Due to metabolic syndrome is a pathological condition in which numerous metabolic abnormalities aggregates, its occurrence is relates to insulin resistance, becoming a hot spot in the research field of cardiovascular diseases and diabetes, and raising many controversies at home and abroad. In addition, metabolic syndrome accompanies with disorder of intestinal microecosystem. Disorder of intestinal microecosystem may further lead to disorder of intestinal functions, nerve center functions and peripheral nerve functions, for example, intestinal inflammation, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), abnormality of neurotransmitter 5-hydroxytryptamine level and level of some hormone and so on. Many researches have shown that abundances of intestinal microbes of some genus have intimate connection with intestinal diseases, for example, the abundance of Blautia genus will rise in intestinal flora of IBS patient, and the abundance of Oscillospira genus is closely related to the body mass index. At the same time, researches also show that mental diseases such as depression, anxiety and so on have intimate connection with metabolic syndrome, intestinal flora disorder, and low 5-hydroxytryptamine level in human body. Improving 5-hydroxytryptamine level in peripheral blood helps increasing neurotransmitter level of central nervous system, so that relieving symptoms of anxiety, depression and so on.
At present, all the drug treatments of metabolic syndrome aim to decrease all kinds of risk factors, and these drugs include: anti-obesity drugs for weight loss; dimethylbiguanide and thiazolidinediones for reducing insulin resistance; sulfonylurea and rosiglitazone for controlling blood glucose; fibrate and statin for improving disorder of lipid metabolism; captopril, amlodipine and so on for controlling the blood pressure; drugs for treating intestinal diseases such as IBD, IBS and so on, including glucocorticoid, immunosuppressant, psychotropic drugs and so on; drugs for mental diseases such as anxiety, depression and so on, including selective serotonin reuptake inhibitors such as paroxetine, noradrenaline, and specific 5-hydroxytryptamine antidepressant drugs such as mirtazapine and so on. All of the medicines above have certain therapeutic effects, but as the conditions getting worse, the amounts of medicine used increase, the interactions between the medicines as well as the toxic and side effects of medicines become significant, leading to adverse reaction of digestive tract and showing liver and renal toxicity in some degree. In consideration of problems of the medicines, early intervention in metabolic syndrome, intestinal disease and mental disease can effectively decrease onset risk of cardiovascular and cerebrovascular diseases, diabetes, inflammatory bowel diseases, depression and so on.
Probiotics are edible microbes that are beneficial to human health, which have potential functions of alleviating abnormal metabolism of blood glucose and blood lipid, and modulating intestinal flora proportion and brain-gut axis. Thus, there is important social and economy value to research and develop probiotic products that can effectively intervene the occurrence and development of metabolic syndrome, intestinal diseases and mental diseases.
At present, there is no patent about using probiotics to increase 5-hydroxytryptamine level so as to regulate brain-gut axis and relieve anxiety and depression. There is also no patent about modulating the abnormal abundance of Oscillospira genus to relieve metabolic diseases. Although there is related patent application (CN107083339A) that discloses adding Blautia bacteria to protect piglets from diarrhea, there is no patent about modulating the abnormal abundance of Blautia genus bacteria in intestinal tract so as to alleviate intestinal disease by the uptake of edible microbes (list of bacterium that can be permitted to be used in food, infant food, health products by National Health Commission of the People's Republic of China, 2014). In addition, there are some patents or patent application relating to compositions and preparation method thereof for preventing and curing metabolic syndrome. For example, CN104906263A discloses a composition consisting of tea polyphenol, procyanidin and POTENTILLAE DISCOLORIS HERBA extract, which is used to treat metabolic syndrome. CN105796674A discloses a traditional Chinese medicine composition comprising PLANTAGINIS SEMEN, COPTIDIS RHIZOMA and so on, which is capable of preventing and curing metabolic syndrome. In addition, a few patents relate to probiotics-containing compositions that are used to improve metabolic syndrome, and the methods for preparing the same. For example, CN105816623A discloses a probiotic-fermented traditional Chinese medicine composition being used to cure and improve metabolic syndrome, which is made from traditional Chinese medicine such as PANACIS QUINQUEFOLII RADIX, DIOSCOREAE RHIZOMA, MOUTAN CORTEX, PORIA by extracting and fermenting the extract with probiotics. All the above patents and patent applications are using traditional Chinese medicine components or a mixture of bacteria and traditional Chinese medicine to alleviate metabolic syndrome, in which the bacteria and the functions of the bacteria are not clear. CN105567586A discloses a Lactobacillus plantarum NCU116 with antidiabetic function, which achieves antidiabetic effects through modulating body blood glucose, blood lipid, hormone level and body metabolism. The Lactobacillus plantarum is screened and selected from bacteria in kimchi instead of human sources. No evidence shows that Lactobacillus plantarum can colonize in human intestinal tract and take effects. So far, there is no a human-sourced individual probiotic (such as Lactobacillus reuteri) that can colonize in human intestinal tract to relieve the metabolic syndrome, or to alleviate symptoms such as hyperglycemia, hyperlipidemia, intestinal flora imbalance, intestinal inflammation and so on, and related mental diseases.
In view of above, an object of the present disclosure is to solve the problems in the prior art by providing a probiotics. The probiotics can colonize in intestinal tract of human body, improve 5-hydroxytryptamine level in peripheral blood, regulate brain-gut axis and recovering testosterone level in serum back to normal level, normalize abnormal abundances of Blautia genus, Turicibacter genus, Oscillospira genus and Bifidobacterium genus in intestinal flora, improve metabolic syndrome, relieve hyperglycemia, hyperlipidemia and inflammation of liver and duodenum, liver fibrosis and other symptoms.
The present disclosure provides a strain CCFM8631 of Lactobacillus reuteri, which is deposited at China General Microbiological Culture Collection Center (CGMCC, Address: Beijing Institute of Microbiology, Chinese Academy of Sciences, No. 1, Beichen West Road, Chaoyang District, Beijing, China) on Jul. 7, 2017, with an accession number CGMCC 14394.
In one embodiment, the present disclosure studies effect of strain CCFM8631 of Lactobacillus reuteri on intestinal flora imbalance caused by high-carbohydrate and high-fat diet. The results show that the uptake of strain CCFM8631 of Lactobacillus reuteri significantly recovers relative abundances of Bifidobacterium genus and Turicibacter genus in disordered intestinal microbes of rat feces, and also regulates the abundances of Oscillospira genus and Blautia genus in rat feces back to normal level. The intervention effect is obviously better than that of Lactobacillus rhamnosus LGG.
In one embodiment, the present disclosure studies protection effects of strain CCFM8631 of Lactobacillus reuteri on tissue damages of liver, duodenum and so on in rat with metabolic syndrome. The results show that administration of strain CCFM8631 of Lactobacillus reuteri by intragastric gavage significantly improves symptoms caused by high-fat high-starch diet, such as hepatocyte microvesicular steatosis, interstitial inflammatory cell infiltration, early fibrosis of liver tissue, duodenum villi broadening, interstitial edema, increasing of inflammatory cells and so on in rats, and the intervention effect is obviously better than that of Lactobacillus rhamnosus LGG.
In one embodiment, the present disclosure studies effect of strain CCFM8631 of Lactobacillus reuteri on (fasting) blood glucose level of rat with metabolic syndrome. The results show that administration of strain CCFM8631 of Lactobacillus reuteri by intragastric gavage obviously decreases the fasting blood glucose level of the model rat close to the blank control group. The ability of strain CCFM8631 of Lactobacillus reuteri on decreasing fasting blood glucose level of rat is better than that of rosiglitazone and Lactobacillus rhamnosus LGG by intragastric gavage administration.
In one embodiment, the present disclosure studies effect of strain CCFM8631 of Lactobacillus reuteri on oral glucose tolerance of rat with metabolic syndrome. The results show that strain CCFM8631 of Lactobacillus reuteri significantly improves oral glucose tolerance and the effect is better than that of Lactobacillus rhamnosus LGG, indicating that strain CCFM8631 of Lactobacillus reuteri can further decrease glucose level by improving glucose tolerance.
In one embodiment, the present disclosure studies effects of strain CCFM8631 of Lactobacillus reuteri on total cholesterol (TC) and triglyceride (TG) in serum of rat with metabolic syndrome, respectively. The results show that administration of strain CCFM8631 of Lactobacillus reuteri by intragastric gavage decreases levels of total cholesterol and triglyceride in serum.
Further, in one embodiment, the present disclosure studies effects of strain CCFM8631 of Lactobacillus reuteri on 5-HT and testosterone level in serum of rat with metabolic syndrome, respectively. The results show that administration of strain CCFM8631 of Lactobacillus reuteri by intragastric gavage improves 5-hydroxytryptamine (5-HT) level in rat serum, and reduces testosterone in serum back to normal level.
Therefore, the present disclosure provides use of strain CCFM8631 of Lactobacillus reuteri in preparing products that can improve metabolic syndrome, regulate intestinal flora or regulate brain-gut axis.
Therein, the improving metabolic syndrome is to relieve symptoms of hyperglycemia and hyperlipidemia, inflammation of liver and duodenum, and liver tissue fibrosis; the modulating intestinal flora is to normalize abnormal abundances of Blautia genus, Turicibacter genus, Oscillospira genus and Bifidobacterium genus in intestinal flora; and the modulating brain-gut axis as well as relieving anxiety and depression is to increase 5-hydroxytryptamine level in peripheral blood.
The product of the present disclosure includes but is not limited to health food or pharmaceutical preparation.
Therein, the health food includes but is not limited to microbial agent or fermented food.
Further, the present disclosure provides a microbial agent comprising the strain CCFM8631 of Lactobacillus reuteri.
Preferably, the viable count of the strain CCFM8631 of Lactobacillus reuteri in the microbial agent is more than 106 CFU/g
The microbial agent of the present disclosure can be prepared by routine methods.
In some embodiments, the method for preparing the microbial agent is:
inoculating the strain CCFM8631 of Lactobacillus reuteri to a modified MRS medium at an inoculum size of 2 to 4 wt %, culturing for 18 to 20 h at 37° C. under anaerobic conditions, collecting bacteria, resuspending the bacteria with a protectant to reach a bacterial density of 1010 CFU/mL, culturing the suspension at 37° C. for 50 to 70 minutes under anaerobic conditions, and drying the resulting culture.
Therein, the modified MRS medium (MRS) in the present disclosure is prepared by the specific method as follows: dissolving 10 g of tryptone, 10 g of beef extract, 5 g of yeast powder, 20 g of glucose, 5 g of sodium acetate, 2 g of ammonium citrate dibasic, 2 g of dipotassium hydrogen phosphate, 0.5 g of magnesium sulfate heptahydrate, 1 mL of Tween-80, and 0.25 g of manganese sulfate monohydrate in water, diluting the mixture to 1000 mL with water, modulating the pH to 6.5, and autoclaving at 119-123° C. for 15 to 25 minutes.
The protectant in the method of the present disclosure is an aqueous solution that contains 100 g/L to 150 g/L of nonfat milk powder, 100 g/L to 150 g/L of maltodextrin and 140 g/L to 160 g/L of trehalose. That is, the protectant consists of nonfat milk powder, maltodextrin, trehalose and water, wherein the concentration of nonfat milk powder is from 100 g/L to 150 g/, the concentration of maltodextrin is from 100 g/L to 150 g/L, and the concentration of trehalose is from 140 g/L to 160 g/L.
Preferably, in the method of the present disclosure, bacteria collected after culturing in the modified MRS medium are subjected to washing with phosphate buffer solution for 2 to 4 times, and pH of the phosphate buffer solution is from 6.8 to 7.2.
The drying of the method in the present disclosure can be any of the drying procedures for bacteria solution, for example vacuum freeze-drying. In some embodiments, the drying of the present disclosure is vacuum freeze-drying after pre-freezing the bacteria at −15 to −20° C. for 8 to 14 h.
The present disclosure also provides a fermented food which is produced by using the strain CCFM8631 of Lactobacillus reuteri as a starter culture.
The fermented food is fermented dairy products, fermented bean products or fermented fruit and vegetable products.
The fermented dairy products include but are not limited to yogurt, sour cream and cheese. The fermented bean products include but are not limited to soymilk, fermented beans and bean paste. The fruits and vegetables in the fermented fruit and vegetable products include but are not limited to cucumber, carrot, beet, celery and cabbage.
The present disclosure also provides a pharmaceutical preparation, comprising an effective amount of the strain CCFM8631 of Lactobacillus reuteri and a pharmaceutically acceptable adjuvant.
The pharmaceutically acceptable adjuvant is one or more selected from the group consisting of filler, adhesive, wetting agent, disintegrating agent, lubricant, and flavoring agent.
In some embodiments of the present disclosure, the pharmaceutical preparation is a granule, a capsule, a tablet, a pill or an oral liquid.
The beneficial technical effects of the present disclosure are as follows.
The strain CCFM8631 of Lactobacillus reuteri of the present disclosure significantly increases neurotransmitter 5-hydroxytryptamine (5-HT) level in peripheral blood of rat, regulates brain-gut axis, relieves mental illnesses related to metabolic syndrome, for example anxiety, depression and so on, recovers the hormone level, for example testosterone and so on in peripheral blood of rat caused by high-fat high-starch diet, recovers abundances of Blautia genus, Turicibacter genus, Oscillospira genus and Bifidobacterium genus in abnormal intestinal flora of rat caused by high-fat high-starch diet. In addition, strain CCFM8631 of Lactobacillus reuteri has pretty good tolerance to simulated gastrointestinal fluid, and quickly colonizes in intestinal, significantly alleviates pathology damages of tissues, such as liver, duodenum and so on of rat with metabolic syndrome caused by high-fat high-starch diet; significantly improves oral glucose tolerance of rat with metabolic syndrome and decreases the under curve area of glucose tolerance test; significantly increases triglyceride and total cholesterol levels in serum of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8631 of Lactobacillus reuteri of the present disclosure can be used to prepare health foods or medicines that improve metabolic syndrome, regulates intestinal flora, relieves irritable bowel syndrome, regulates brain-gut axis and alleviates mental illness such as anxiety, depression and so on, which has a pretty wide application prospect.
CCFM8631, classification name: Lactobacillus reuteri, is deposited at China General Microbiological Culture Collection Center (CGMCC, Address: Beijing Institute of Microbiology, Chinese Academy of Sciences, No. 1, Beichen West Road, Chaoyang District, Beijing, China) on Jul. 7, 2017, with an accession number CGMCC 14394.
In order to describe the technical solutions in the examples of the present disclosure or the conventional art more clearly, the accompanying drawings used in description of the embodiments or the prior art will be illustrated briefly.
The present disclosure discloses a Lactobacillus reuteri and use thereof. One of ordinary skill in the art can learn from the contents herein and improve the process parameters appropriately. In particular, it shall be noted that all the similar substitutions and modifications are apparent to one of ordinary skill in the art and are to be considered within the scope of the present invention. The method and product of the present invention have been described with preferred examples. It is apparent that one of the ordinary skill in the art can make change or modify the combination to the method and product of the present invention without departing from the spirit, scope and spirit of the invention, therefore realizing and applying the techniques of the present invention. www
The strain CCFM8631 of Lactobacillus reuteri of the present disclosure has the following biology properties.
(1) Bacterium properties: Gram straining positive, slim rod-shape, no flagella, no spore
(2) Colony properties: convex colonies are formed after 36-hour culture, the edge is not smooth, the color is milky and non-transparent, the surface is moist and smooth, and no pigment is produce. See
(3) Growth properties: the bacteria are cultured in MRS medium for about 18 hours at constant temperature of 37° C. to reach log phase.
(4) Good tolerance to simulate gastrointestinal fluid.
(5) Significantly improve pathological tissue damages such as liver, duodenum and so on of rat with from metabolic syndrome.
(6) Significantly improve oral glucose tolerance of rat with metabolic syndrome.
(7) Decrease area under the curve in glucose tolerance test.
(8) Regulate the levels of triglyceride and total cholesterol in serum back to normal level.
(9) Increase 5-hydroxytryptamine (5-HT) level in peripheral blood and regulate testosterone to normal level.
(10) Significantly recover abundances of Bifidobacterium genus, Turicibacter genus, Oscillospira genus, Blautia genus and so on in abnormal intestinal flora caused by high-fat high-starch diet.
The strain CCFM8631 of Lactobacillus reuteri of the present disclosure is obtained by the following method.
I. Isolation and Screening of Lactobacillus
(1) 1 g of fresh feces was diluted in gradient, spreaded on Lactobacillus highly selected solid medium plates (0.05 g bromocresol green, 0.02 g vancomycin, 20 g agar per 1 L MRS medium, pH 5.0±0.1), and the plates were incubated at 37° C. for 48-72 hours. The feces were obtained from a 57-year-old healthy female in Changshou Village, Bama Town in Guangxi Province, China.
(2) Morphology of the colonies were observed and recorded, and single colony was picked out and purified by streaking.
(3) The bacteria were cultured at 37° C. for 24 hours in MRS medium, and the colonies obtained were subjected to Gram staining. The morphologies of the colonies were recorded.
(4) The Gram-negative strains and Gram-positive cocci were discarded, the Gram-positive bacilli were selected.
(5) The bacteria were subjected to catalase analyzing, the catalase-positive strains were discarded and catalase-negative strains were retained.
II. Molecular Biological Identification of Lactobacillus reuteri
(1) Genome extraction of single bacterium (according to operation procedures of TIANamp Bacteria DNA kit)
A. The Lactobacillus obtained in Step I was cultured overnight. 1 mL culture was put into a 1.5 mL centrifuge tube and centrifuged at 10,000 rpm (˜11,500×g) for 1 minute. The supernatant was removed as much as possible.
B. 180 μL buffer (20 mg/mL lysozyme solution with 20 mM Tris (pH 8.0), 2 mM Na2-EDTA, and 1.2% Triton) was added to the bacteria and incubated at 37° C. for more than 30 minutes. (The lysozyme solution should be prepared by dissolving lysozyme dry powder in the buffer, or the lysozyme would be inactive.
C. 20 μL Proteinase K solution was added to the tube and mixed well.
D. 220 μL buffer GB was added, shaken for 15 seconds, and placed at 70° C. for 10 minutes. The solution turned clean. The tube was centrifuged for a few seconds to remove water drops on inner wall of the tube.
E. 220 μL absolute alcohol was added adequately shaken for 15 seconds. Flocculent precipitates maybe appear. The tube was centrifuged for a few seconds to remove water drops on inner wall of the tube.
F. The solution and flocculent precipitate obtained in the last step were put into an adsorption column CB3 (the absorption column was disposed in a collecting tube), and subjected to centrifugation at 12,000 rpm (˜13,400×g) for 30 seconds. The flow-through liquor was discarded, and the adsorption column was put back into the collecting tube.
G. 500 μL of buffer GD (check for absolute alcohol adding before use) was added to the adsorption column CB3. The column was centrifuged at 12,000 rpm (˜13,400×g) for 30 seconds. The flow-through liquor was discarded, and the adsorption column was put back into the collecting tube.
H. 600 μL of washing solution PW (check for absolute alcohol adding before use) was added to the adsorption column CB3. The column was centrifuged at 12,000 rpm (˜13,400×g) for 30 seconds. The flow-through liquor was discarded, and the adsorption column was put back into the collecting tube. This step was repeated once.
I. The adsorption column CB3 was put back into the collecting tube, centrifuged at 12,000 rpm (˜13,400×g) for 2 minutes, and the flow-through liquor was discarded. The adsorption column CB3 was placed at room temperature for a few minutes to let the adsorption column totally dry.
J. The adsorption column CB3 was transferred to a clean centrifugal tube, and 50 to 200 μL of elution buffer TE was dropped to the middle of the adsorption film. The adsorption column was placed at room temperature for 2 to 5 minutes, and then centrifuged at 12,000 rpm (˜13,400×g) for 2 minutes. The eluted solution was collected into a centrifuge tube.
(2) Whole Genome Sequencing
The extracted whole genome was sent to a professional sequencing company and a third-generation sequencer was used to sequence the whole bacterial genome. The sequencing results were subjected to similarity comparison by BLAST software among GeneBank database. The results show that the strain provided by the present disclosure is a Lactobacillus reuteri, but different from known Lactobacillus reuteri, so that it is identified as a new strain. By blastn algorithm, the genome of strain CCFM8631 of Lactobacillus reuteri was compared with that of standard strain DSM20016 of Lactobacillus reuteri (https://wwwncbi.nlm.nih.gov/genome/?term=438), 571 genes in total show differences, which are shown in Table 1.
reuteri
reuteri I5007]
reuteri]
reuteri I5007]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri I5007]
reuteri]
reuteri I5007]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri I5007]
reuteri I5007]
reuteri]
reuteri]
reuteri]
reuteri I5007]
reuteri]
reuteri]
reuteri CF48-3A]
reuteri CF48-3A]
reuteri]
reuteri]
reuteri SD2112]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri MM2-3]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri I5007]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri I5007]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri 100-23]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri DSM 20016]
reuteri MM2-3]
reuteri DSM 20016]
reuteri]
reuteri]
reuteri DSM 20016]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri DSM 20016]
reuteri]
reuteri]
reuteri DSM 20016]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri DSM 20016]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri]
reuteri]
reuteri ATCC 53608]
reuteri I5007]
reuteri ATCC 53608]
reuteri]
reuteri]
reuteri I5007]
reuteri]
reuteri]
reuteri]
reuteri]
The beneficial technical effects of the present disclosure are as follows.
The strain CCFM8631 of Lactobacillus reuteri of the present disclosure significantly increases neurotransmitter 5-hydroxytryptamine (5-HT) level in peripheral blood of rat, regulates brain-gut axis, relieves mental illnesses related to metabolic syndrome, for example anxiety, depression and so on, recovers the hormone level, for example testosterone and so on in peripheral blood of rat caused by high-fat high-starch diet, recovers abundances of Bifidobacterium genus, Turicibacter genus, Oscillospira genus and Blautia genus in abnormal intestinal flora of rat affected by high-fat high-starch diet. In addition, strain CCFM8631 of Lactobacillus reuteri has pretty good tolerance to simulated gastrointestinal fluid, and quickly colonizes in intestinal, significantly alleviates pathology damages of tissues, such as liver, duodenum and so on of rat with metabolic syndrome caused by high-fat high-starch diet; significantly improves oral glucose tolerance of rat with metabolic syndrome and decreases the under curve area of glucose tolerance test; significantly increases triglyceride and total cholesterol levels in serum of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8631 of Lactobacillus reuteri of the present disclosure can be used to prepare health foods or medicines that improve metabolic syndrome, regulates intestinal flora, relieves irritable bowel syndrome, regulates brain-gut axis and alleviates mental illness such as anxiety, depression and so on, which has a pretty wide application prospect.
In order to understand the present disclosure further, the technical solutions in the examples of the present disclosure will be described clearly and completely herein in conjunction with the examples of the present disclosure. Apparently, the described examples are only a part of the examples of the present disclosure, rather than all examples. Based on the examples in the present disclosure, all of other examples, made by one of ordinary skill in the art without any creative efforts, fall into the protection scope of the present disclosure.
All of the reagents related to examples of the present disclosure are commercial products without special description, which can be purchased on market. All of the following examples are completed by theory and technology research group of probiotics of Research Center of Food Biotechnology in School of Food Science and Technology, Jiangnan University.
The cryopreserved strain CCFM8631 of Lactobacillus reuteri were inoculated in the MRS medium and cultured at 37° C. for 48 hours under anaerobic cultivation, followed by 2 to 3 times subculture in MRS liquid medium. The medium with strain CCFM8631 of Lactobacillus reuteri was taken and centrifuged for 5 minutes at a speed of 8000 g, and then resuspended (1:1) in an artificial simulated gastric juice (MRS medium containing 1% pepsin, pH 2.5), followed by anaerobic cultivation at 37° C. Sampling was carried out at 0 hour and 3 hours, and the samples were cultured on MRS medium agar plate for colony counting. The viability numbers were counted and the survival rates were calculated. The survival rate is the rate of the viable count at the desired time point to the viable count at the 0 hour, which was expressed in %.
The medium with cultured strain CCFM8631 of Lactobacillus reuteri was taken and centrifuged at a speed of 8000×g for 5 minutes. The bacteria were collected and resuspened (1:1) in artificial simulated intestinal fluid (MRS medium containing 0.3% bile salt from ox, 1% trypsin, pH 8.0), followed by anaerobic cultivation at 37° C. Sampling was carried out at 0 hour and 4 hours, and the samples were cultured on MRS medium agar plate for colony counting. The viability numbers were counted and the survival rates were calculated. The survival rate is the rate of the viable count at the desired time point to the viable count at the 0 hour, which was expressed in %.
The experiment results were shown in Table 2. The results showed that strain CCFM8631 of Lactobacillus reuteri has a relative good tolerance to simulated gastrointestinal fluid.
The strain CCFM8631 of Lactobacillus reuteri bacteria were resuspended in 2% sucrose solution to give a bacterial suspension with a concentration of 3.0×109 CFU/mL. 8 healthy male SD rats with a weight between 180 and 200 g were chosen and acclimated for 1 week before experiments. The rats were administered with the above bacteria suspension by intragastric gavage once daily at a dose of 2 mL/day/rat. The death and weight of the rats were observed and recorded for one week. The results were shown in Table 3.
The results showed that administration of strain CCFM8631 of Lactobacillus reuteri with a concentration of 3.0×109 CFU/mL did not have significant influences on rats, there was no significant change on the body weight and no death. There were no obvious pathological symptoms in the appearance of the rats.
48 healthy male SD rats with weight from 180 to 200 g were chosen and acclimated for 1 week. The rats were divided into 6 groups randomly: non-specific control group (NC), high-fat high-starch (HFHS) diet model control group, simvastatin control group (SC), rosiglitazone hydrochloride control group (RH), strain CCFM8631 of Lactobacillus reuteri intervention group (CCFM8631), Lactobacillus rhamnosus LGG control group (LGG), 8 rats per group. The rats were administered with the bacteria suspension (3.0×109 CFU/mL, in 2% sucrose solution) by intragastric gavage. Grouping and treatment method were shown in Table 4.
At the end of the experiment, the rats were fasted (with access to water) for 12 hours. After administering 10% chloral hydrate by peritoneal injection, the rats were anesthetized, the blood samples were collected from the hearts, and the rats were sacrificed by cervical dislocation. The blood samples were centrifuged at a speed of 3000×g at 4° C. for 10 minutes. The supernatant was collected and frozen at −80° C. for later use. Liver, duodenum and so on were collected and quickly put into ice-cold physiological saline to wash away the blood, followed by fixation in paraformaldehyde. In addition, small intestine was collected and immediately frozen in liquid nitrogen.
Intestine, duodenum and so on were taken and prepared as paraffin sections, followed by HE straining. Morphology of the tissues were observed and imaged under optical microscope for pathological evaluation. The results were shown in
(1) Fixation: the tissue samples were washed with physiological saline and immediately put into neutral paraformaldehyde solution (4%) for fixation, and the duration of fixation was generally within 72 hours.
(2) Washing: the tissue samples were washed with running water or immersed in water for a few hours or overnight.
(3) Dehydration: the tissue samples were dehydrated by successively immersing in ethanol solutions of 70%, 80% and 90%, each for 30 minutes, and then immersing in 95% ethanol solution once for 20 minutes, immersing in 100% ethanol solution twice, each time for 10 minutes.
(4) Transparency: the tissue samples were immersed in a mixture of ½ absolute ethanol and ½ xylene for 10 minutes, xylene I for 10 minutes, and xylene II for 10 minutes (until the samples became transparent).
(5) Waxing: the tissue samples were placed in paraffin (at 62° C.) for 2 hours.
(6) Embedding: the largest side of the sample was placed in the bottom so that the sections have the largest tissue surface.
(7) Cutting: the wax blocks were cut by a manually operating microtome into slices with a thickness of 5 μm.
(8) Floatation and adhesion of sections (slice-salvaging): a water bath was used and the water was maintained at 42° C.; sections were placed onto the water surface smoothly.
(9) Drying: slides and slide rack were put into a 55° C. drying oven for about 2 hours until the wax melted.
(10) Hydration: slides were immersed in xylene I and II for 10 minutes respectively for dewaxing, and then immersed in ethanol solutions of 100%, 95%, 90%, 80% and 70% for 5 minutes respectively, and then immersed in distilled water for 3 minutes.
(11) Primary strain: the slides were put into hematoxylin solution and strained for about 20 seconds.
(12) Washing: the slides were washed with tap water for about 15 minutes until the slices became blue. Pay attention to the water flow to avoid the sections detaching from the slide.
(13) Differentiation: the slides were put into ethanol solution with 1% hydrochloric acid for 7 seconds until the slices turned red (the color became light).
(14) Rinsing: the slides were washed with tap water for 15 to 20 minutes until the color recovered blue.
(15) Re-stain: the slides were immersed in eosin solution and immediately taken out for dehydration.
(16) Dehydration: the slides were immersed in 95% ethanol solution I, 95% ethanol solution II and 70% ethanol solution successively, followed by immersing in 80% ethanol solution for 50 seconds and absolute ethanol for 2 minutes.
(17) Transparency: the slides were immersed in ½ of absolute ethanol and ½ of xylene for 1 minute, xylene I for 2 minutes and xylene II for 2 minutes, respectively.
(18) Sealing: after the treatment of xylene, the neutral balsam was used as mounting medium, which could be diluted to appropriate consistency with xylene.
Grouping, molding and treatment processes using SD rats were the same as described in Example 3. Before the end of the experiment, fresh feces of the rats were taken and metagenome samples were extracted. A second-generation sequencer was used for sequencing and the microbial community structure was analyzed.
The experiment results were shown in
Grouping, molding and treatment processes using SD rats were the same as described in Example 3.
At the end of the experiment the rats were fasted (with access to water) for 12 hours and fasting blood glucose level of the rats was tested. The results were shown in
In high-fat high-starch diet model control group (HFHS), fasting blood glucose level of rats significantly increased. In strain CCFM8631 of Lactobacillus reuteri intervention group (CCFM8631), administration of strain CCFM8631 of Lactobacillus reuteri by intragastric gavage significantly decreased fasting blood glucose level of model rats, approximately to non-specific control group, and its ability to decrease fasting blood glucose level of rat is better than that of rosiglitazone hydrochloride control group (RH) and Lactobacillus rhamnosus LGG control group (LGG).
Grouping, molding and treatment processes using SD rats were the same as described in Example 3. At the end of the experiment, the rats were fasted (with access to water) for 12 hours. Glucose solution (2 g/kg) was injected by intraperitoneal injection and the blood glucose level was measured at 0, 30, 60 and 120 minutes. The experiment results were shown in
As shown in
Grouping, molding and treatment processes using SD rats were the same as described in Example 3. At the end of the experiment, the rats were fasted (with access to water) for 12 hours. After administering 10% chloral hydrate by peritoneal injection for anesthetizing, blood sample was collected from the heart, and the rats were sacrificed by cervical dislocation. The blood samples were centrifuged at a speed of 3000×g at 4° C. for 10 minutes, and the supernatant was collected. The total cholesterol (TC) in the blood was measured according to the protocol of the detection kit. The experiment results were shown in
As shown in
Grouping, molding and treatment processes using SD rats were the same as described in Example 3. At the end of the experiment, the rats were fasted (with access to water) for 12 hours. After administering 10% chloral hydrate by peritoneal injection for anesthetizing, blood sample was collected from the heart, and the rats were sacrificed by cervical dislocation. The blood samples were centrifuged at a speed of 3000×g at 4° C. for 10 minutes, and the supernatant was collected. The triglyceride (TG) level in the blood was measured according to the protocol of the detection kit. The experiment results were shown in
As shown in the experiment results, comparing with non-specific control group (NC), triglyceride level in serum of rats in high-fat high-starch diet model control group significantly increased. In strain CCFM8631 of Lactobacillus reuteri intervention group, administration of strain CCFM8631 of Lactobacillus reuteri by intragastric gavage decreased triglyceride level in serum, and the effect was better than that of LGG
Grouping, molding and treatment processes using SD rats were the same as described in Example 3. At the end of the experiment, the rats were fasted (with access to water) for 12 hours. After administering 10% chloral hydrate by peritoneal injection for anesthetizing, blood sample was collected from the heart, and the rats were sacrificed by cervical dislocation. The blood samples were centrifuged at a speed of 3000×g at 4° C. for 10 minutes, and the supernatant was collected. The 5-HT and testosterone levels in the blood were measured according to the protocol of the detection kit.
The experiment results were shown in
Number | Date | Country | Kind |
---|---|---|---|
201710963119.2 | Oct 2017 | CN | national |
Number | Date | Country |
---|---|---|
104413334 | Mar 2015 | CN |
104561227 | Apr 2015 | CN |
104771416 | Jul 2015 | CN |
104887716 | Sep 2015 | CN |
105030950 | Nov 2015 | CN |
105853467 | Aug 2016 | CN |
Entry |
---|
Simon et al (Intake of Lactobacillus reuteri Improves Incretin and Insulin Secretion in Glucose-Tolerant Humans: A Proof of Concept , American diabetes Association, Oct. 2015 (Year: 2015). |
Mu et al (frontiers in Microbiology, Role of Lactobacillus reuteri in Human Health and Diseases, Apr. 19, 2018) (Year: 2018). |
Carabotti et al ( Annals of Gastroenterology The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems, Jun. 2015). (Year: 2015). |
First Office Action dated Jul. 3, 2019 for Chinese patent application No. 201710963119.2, 7 pages. |
Wang Lu et al., Microbial euphoria, Shanghai Science and Technology,Dec. 31, 2015. |
Cui Xin-yao et al., The approach to structure and function of gut microbiota in patients with depressive syndrome, Chinese Journal of Microccology, vol. 27 No. 10, Oct. 31, 2015. |
Zhu Guang-su et al., Safety assessment of two probiotic strains with the function of metabolic syndrome alleviation isolated from human gut, Food and Fermentation Industries, 44(8) :57-64, Oct. 17, 2018. |
Number | Date | Country | |
---|---|---|---|
20190112675 A1 | Apr 2019 | US |